The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For October 28, 2021
Companies Reporting Before The Bell
• LendingTree (NASDAQ:TREE) is estimated to report quarterly earnings at $0.57 per share on revenue of $292.63 million.
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength.
PleasrDAO Aint Nothing To F*** With: Wu Tang Clan Album Once Owned By Shkreli Has Been Purchased
From the slums of Shaolin, Wu-Tang Clan strikes again. An exclusive album made by the legendary hip-hop group is back in the news with the latest anonymous buyer of the album being revealed earlier this week.
8 Health Care Stocks With Unusual Options Alerts In Today’s Session
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Unusual trading activity could push option prices to hyperbolic or underperforming levels.
Here's the list of some unusual options activity happening in today's session:
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 15)
Travere Therapeutics And Vifor Pharma Announce Licensing Agreement For The Commercialization Of Sparsentan In Europe, Australia And New Zealand
Vifor Pharma obtains exclusive commercialization rights for sparsentan in Europe, Australia and New Zealand
Travere receives a $55 million upfront payment and is eligible for additional regulatory and
See Why Travere Therapeutics Stock Moving Higher On Tuesday
Travere Therapeutics Inc (NASDAQ:TVTX) has concluded a Type A meeting with the FDA related to sparsentan in focal segmental glomerulosclerosis (FSGS). …